A randomized, investigator and participant-blind, adaptive, multiple ascending dose, placebo-controlled, parallel phase I study to investigate the safety, tolerability, pharmacokinetics (including the effect of itraconazole on RO7268489 pharmacokinetics), and pharmacodynamics of RO7268489 following oral administration in healthy participants

F. Hoffmann-La Roche Ltd0 个研究点目标入组 68 人开始时间: 2024年5月10日最近更新: 2024年6月18日

试验速览

暂无简介。

•1.Male or female participants aged 18 - 64 years, who are overtly healthy (defined by absence of evidence of any active or chronic disease)
•2.BMI within the range of 18.5 to 30 kg/m² (inclusive)

•1.History of malignancy in the past 5 years.
•2.History of any clinically significant psychiatric disorder.
•3.History of severe unpleasant experience following the use of cannabis-containing products
•4.History or evidence of any medical condition potentially altering the absorption, metabolism, or elimination of drugs.
•5.Any contraindications for magnetic resonance imaging (MRI) scans or any brain/head abnormalities restricting MRI eligibility (Part 1 only).
•6.Vaccination within 2 weeks prior to Day 1 including influenza and/or SARS-CoV-2/ COVID-19 vaccination

发起方